Paratek Pharmaceuticals Inc   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Boston MA United States (1996)

Organization Overview

First Clinical Trial
2007
NCT03716024
First Marketed Drug
2018
omadacycline (nuzyra)
First NDA Approval
2018
omadacycline (nuzyra)
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Paratek Pharmaceuticals | Paratek Pharmaceuticals Inc | PARATEK PHARMS INC